newsfilter
← Latest News
Business Wire·

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 - PIPE-791 chronic toxicity studies completed to support future Phase 2 trials - Topline data from